Svein Isungset Støve
Position
Guest Researcher, Researcher KG Jebsen centre for Parkinsons disease
Affiliation
Research groups
- KG Jebsen Centre for Parkinson’s Disease
- DECODE-PD
- Structural Biology and Drug Discovery unit
- Biorecognition
Publications
Conference poster
- Tollan Sommer Inga Elise; Aurora Martinez; Svein Isungset Støve (2022). Screening for modulators of vesicular monoamine transporter 2 activity in transfected Hek293 cells using a fluorescent substrate.. (external link)
- Trond-André Kråkenes; Fredrik Gullaksen Johannessen; Martin Jakubec et al. (2020). Phosphorylated TH hinges with vesicular membrane proteins for axonal transport. (external link)
- Markus Baumann; Line Merethe Myklebust; Marianne Goris et al. (2018). Inhibition of the Actin N-terminal acetyltransferase NAA80. (external link)
- Chloe Saunier; Christiane Zweier; Svein Isungset Støve et al. (2015). NAA10 missense mutations cause neurodevelopmental delay in eight female patients. (external link)
- Svein Isungset Støve; Petra Van Damme; Line Merethe Myklebust et al. (2014). In silico, in vitro and in vivo models reveal functional impairment of the Ogden syndrome N-terminal acetyltransferase Naa10 S37P mutant. (external link)
- Svein Isungset Støve; Ana Jorge-Finnigan; Kunwar Jung K C et al. (2018). Regulation of protein-protein interactions crucial for dopamine synthesis. (external link)
- Svein Isungset Støve; Åge Aleksander Skjevik; Knut Teigen et al. (2020). Searching for new inhibitors of vesicular monoamine transporter 2 by differential scanning fluorimetry. (external link)
- Gro Haugseng; Mary Dayne Sia Tai; Trond-André Kråkenes et al. (2022). Does alpha-Synuclein modulate Tyrosine Hydoxylase activity?. (external link)
- Åge Aleksander Skjevik; Svein Isungset Støve; Knut Teigen et al. (2020). Identification of VMAT2 inhibitory compounds. (external link)
- Markus Baumann; Line Merethe Myklebust; Håvard Foyn et al. (2020). Inhibition of the Actin N-terminal acetyltransferase NAA80. (external link)
- Svein Isungset Støve; Åge Aleksander Skjevik; Knut Teigen et al. (2022). High-throughput screening for VMAT2 activity modulators. (external link)
- Svein Isungset Støve; Angele Abboud; Cédric Grauffel et al. (2012). An x-linked infantile lethal disorder caused by N-terminal acetyltransferase deficiency. (external link)
- Line Merethe Myklebust; Petra Van Damme; Thomas Vikestad Kalvik et al. (2012). An X-linked infantile lethal disease, the Ogden syndrome, and the functional implications of the hNaa10p S37P mutation. (external link)
- Rasmus Moen Ree; Line Merethe Myklebust; Håvard Foyn et al. (2018). naa10 knockdown and NatA inhibition point to role for the NatA complex in zebrafish dorsoventral axis formation. (external link)
- Svein Isungset Støve; Angele Abboud; Cédric Grauffel et al. (2012). Structural modeling and kinetic studies of a mutant N-terminal acetyltransferase, hNaa10p Ser37Pro, causing an infantile lethal disorder. (external link)
- Fredrik Gullaksen Johannessen; Svein Isungset Støve; Aurora Martinez (2020). Comparing detergent micelles and polymer nanodiscs for solubilization and purification of the integral membrane protein vesicular monoamine transporter 2. (external link)
Academic article
- Håvard Foyn; Petra Van Damme; Svein Isungset Støve et al. (2013). Protein N-terminal acetyltransferases act as N-terminal propionyltransferases in vitro and in vivo. (external link)
- Marianne Goris; Robert S. Magin; Håvard Foyn et al. (2018). Structural determinants and cellular environment define processed actin as the sole substrate of the N-terminal acetyltransferase NAA80. (external link)
- Petra Van Damme; Svein Isungset Støve; Nina Glomnes et al. (2014). A Saccharomyces cerevisiae model reveals in vivo functional impairment of the Ogden syndrome N-terminal acetyltransferase NAA10 Ser37Pro mutant. (external link)
- Stephen Ochaya; Oscar Franzén; Doreen Asiimwe Buhwa et al. (2019). Characterization of Evolutionarily Conserved Trypanosoma cruzi NatC and NatA-N-Terminal Acetyltransferase Complexes. (external link)
- Henriette Aksnes; Petra Van Damme; Marianne Goris et al. (2015). An organellar Nα-acetyltransferase, Naa60, acetylates cytosolic n termini of transmembrane proteins and maintains golgi integrity. (external link)
- Xunan Wang; Ilias Marmouzi; Peter S. B. Finnie et al. (2024). Tricyclic and tetracyclic antidepressants upregulate VMAT2 activity and rescue disease-causing VMAT2 variants. (external link)
- Chloé Saunier; Svein Isungset Støve; Bernt Popp et al. (2016). Expanding the phenotype associated with NAA10-related N-terminal acetylation deficiency. (external link)
- Line Merethe Myklebust; Markus Baumann; Svein Isungset Støve et al. (2023). Optimized bisubstrate inhibitors for the actin N-terminal acetyltransferase NAA80. (external link)
- Svein Isungset Støve; Robert S. Magin; Håvard Foyn et al. (2016). Crystal structure of the Golgi-associated human N-alpha acetyltransferase 60 (Naa60/NatF) reveals the molecular determinants for substrate-specific acetylation.. (external link)
- Nina Mc Tiernan; Svein Isungset Støve; Ingvild Aukrust et al. (2018). NAA10 dysfunction with normal NatA-complex activity in a girl with non-syndromic ID and a de novo NAA10 p.(V111G) variant - a case report. (external link)
- Line Merethe Myklebust; Petra Van Damme; Svein Isungset Støve et al. (2015). Biochemical and cellular analysis of Ogden syndrome reveals downstream Nt-acetylation defects. (external link)
- Jillian P. Casey; Svein Isungset Støve; Catherine McGorrian et al. (2015). NAA10 mutation causing a novel intellectual disability syndrome with Long QT due to N-terminal acetyltransferase impairment. (external link)
- Svein Isungset Støve; Marina Blenski; Asbjørg Stray-Pedersen et al. (2018). A novel NAA10 variant with impaired acetyltransferase activity causes developmental delay, intellectual disability, and hypertrophic cardiomyopathy. (external link)
- Bernt Popp; Svein Isungset Støve; Sabine Endele et al. (2015). De novo missense mutations in the NAA10 gene cause severe non-syndromic developmental delay in males and females. (external link)
- Svein Isungset Støve; Åge Aleksander Skjevik; Knut Teigen et al. (2022). Inhibition of VMAT2 by β2-adrenergic agonists, antagonists, and the atypical antipsychotic ziprasidone. (external link)
- Erna Irene Heggland; Christiane Eichner; Svein Isungset Støve et al. (2019). A scavenger receptor B (CD36)-like protein is a potential mediator of intestinal heme absorption in the hematophagous ectoparasite Lepeophtheirus salmonis. (external link)
Conference lecture
- Svein Isungset Støve (2019). Biophysical studies of a protein complex involved in dopamine synthesis and vesicular packing. (external link)
- Svein Isungset Støve (2012). The Ogden Syndrome. (external link)
- Svein Isungset Støve (2022). High-throughput screening for VMAT2 activity modulators. (external link)
- Svein Isungset Støve (2022). High-throughput screening approaches for vesicular monoamine transporter 2 and mitochondrial complex I. (external link)
- Svein Isungset Støve (2014). N-terminal acetylation and the Ogden syndrome. (external link)
Master’s thesis
- Kristine Kippersund Brokstad; Svein Isungset Støve; Aurora Martinez (2023). Screening for VMAT2 chaperones and activity modulators. (external link)
- Md Ekhtear Mahmud; Svein Isungset Støve; Aurora Martinez (2023). Towards the therapeutic correction of mitochondrial Complex I deficiency in dopaminergic cell models. (external link)